Orchard Therapeutics, the biotech company focused on gene therapies for orphan diseases, has raised $110M in Series B funding from investors that include Temasek Holdings, F-Prime Capital Partners, Baillie Gifford, Cowen Group, RTW Investments LLC, Pavilion Capital, UCL Technology Fund, ORI Capital, 4BIO Capital, Agent Capital and Juda Capital. Founded by Andrea Spezzi and Ben Auspitz in 2015, the company has now raised a total slightly in excess of $160M over two rounds and one grant.